Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) has released its Q3 report for 2025. The company reported a revenue of 510 million yuan for the first three quarters, marking a year-on-year decrease of 29.33%. The net profit attributable to shareholders was 6.1242 million yuan, a significant drop of 95.68% compared to the same period last year. Furthermore, the net loss attributable to shareholders, after excluding non-recurring gains and losses, amounted to 13.9173 million yuan. The basic earnings per share stood at 0.06 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments